Other Events ·
Evogene Ltd. filed a Form 6-K announcing its 2026 Annual General Meeting scheduled for September 4, 2026, with a…
EVGNEvogene Ltd.
Evogene Ltd. filed a Form 6-K announcing its 2026 Annual General Meeting scheduled for September 4, 2026, with a record date of August 11, 2026. The filing discloses that Ms. Olga Nissan stepped down as VP Business Development effective July 31, 2026. Shareholders will vote on a contested director election between the Board's seven-member Evogene Slate and a four-member slate nominated by L.I.A Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd., who hold approximately 14.67% of voting rights. Proposals also include increasing authorized share capital by 120,000,000 shares to NIS 30,000,000 and approving a framework for the Board to execute a reverse stock split at a ratio between 1-for-2 and 1-for-15 within 18 months. Evogene Ltd. operates in the biotechnology industry, focusing on AI-driven computational chemistry and drug discovery.